Guardant Health, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $982.0M | $739.0M | $563.9M | $449.5M | $373.7M |
| Operating income | -$437.2M | -$443.6M | -$564.7M | -$544.4M | -$411.0M |
| Cost of revenue | $349.0M | $289.8M | $227.1M | — | — |
| Cash from operations | -$184.8M | -$239.9M | -$325.0M | -$309.5M | -$209.0M |
| Capital expenditure | $48.3M | $35.1M | $20.5M | $77.5M | $75.0M |
| Free cash flow | -$233.1M | -$274.9M | -$345.5M | -$386.9M | -$284.1M |
| Share repurchases | $45.0M | $0 | $0 | — | — |
| Impairments | $0 | — | — | — | — |
| Total assets | $2.0B | $1.5B | $1.8B | $1.6B | $2.2B |
| Total liabilities | $2.1B | $1.6B | $1.6B | $1.5B | $1.6B |
Shares outstanding 132.6M · Free float 69.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.